There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.

Related collections

Most cited references 91

Record: found
Abstract: found
Article: not found

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Lisa Mosconi (2005)

The demographics of aging suggest a great need for the early diagnosis of dementia and the development of preventive strategies. Neuropathology and structural MRI studies have pointed to the medial temporal lobe (MTL) as the brain region earliest affected in Alzheimer's disease (AD). MRI findings provide strong evidence that in mild cognitive impairments (MCI), AD-related volume losses can be reproducibly detected in the hippocampus, the entorhinal cortex (EC) and, to a lesser extent, the parahippocampal gyrus; they also indicate that lateral temporal lobe changes are becoming increasingly useful in predicting the transition to dementia. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging has revealed glucose metabolic reductions in the parieto-temporal, frontal and posterior cingulate cortices to be the hallmark of AD. Overall, the pattern of cortical metabolic changes has been useful for the prediction of future AD as well as in distinguishing AD from other neurodegenerative diseases. FDG-PET on average achieves 90% sensitivity in identifying AD, although specificity in differentiating AD from other dementias is lower. Moreover, recent MRI-guided FDG-PET studies have shown that MTL hypometabolism is the most specific and sensitive measure for the identification of MCI, while the utility of cortical deficits is controversial. This review highlights cross-sectional, prediction and longitudinal FDG-PET studies and attempts to put into perspective the value of FDG-PET in diagnosing AD-like changes, particularly at an early stage, and in providing diagnostic specificity. The examination of MTL structures, which has so far been exclusive to MRI protocols, is then examined as a possible strategy to improve diagnostic specificity. All told, there is considerable promise that early and specific diagnosis is feasible through a combination of imaging modalities.

0 comments Cited 242 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging.

S G Kim, J. M. Ellermann, D Tank … (1992)

0 comments Cited 227 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.

Lars Bertram, Rudolph E. Tanzi (2008)

The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.

0 comments Cited 204 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

PubMed ID:: 23297785

PMC ID:: 3955298

DOI:: 10.1146/annurev-clinpsy-050212-185535

ScienceOpen disciplines: Chemistry

Keywords: Alzheimer Disease,cerebrospinal fluid,diagnosis,pathology,Biological Markers,Early Diagnosis,Humans,Magnetic Resonance Imaging,methods,Mild Cognitive Impairment,Neuroimaging,Positron-Emission Tomography,Prodromal Symptoms

Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.

Read this article at

Abstract

Related collections

Annual Reviews Top Downloaded Articles in 2020

Most cited references 91

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging.

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.

Author and article information

Journal

Comments

Comment on this article

Similar content 323

Cited by 49

Most referenced authors 3,546